The American College of Chest Physicians, known as CHEST, has published a new framework setting out six steps for building lung nodule programmes — the organised systems hospitals use to make sure that spots found on chest scans are tracked, assessed and, when necessary, biopsied or treated, rather than lost in the shuffle of a busy health system.
A Common Finding With High Stakes
Lung nodules — small spots on the lung — are among the most common incidental findings in modern medicine. Millions of chest CT scans performed for other reasons reveal them every year, and the overwhelming majority are benign: old infections, scars, harmless growths. A small minority, however, are early lung cancers, and for those patients the difference between a nodule that is systematically followed and one that is forgotten can be the difference between a curable cancer and an advanced one.
That is the operational problem the CHEST framework addresses. Finding nodules is easy; modern scanners do it constantly. Managing them well — recording them, risk-stratifying them, communicating with patients, scheduling the right follow-up at the right interval, and escalating the suspicious ones quickly — requires a programme, not good intentions. The framework, published through CHEST, gives institutions a structured path from detection to diagnosis.
Six Steps From Detection to Diagnosis
While the framework’s detail runs deep, its logic is straightforward: a programme must reliably capture every nodule found anywhere in the system; assess each one’s risk using validated criteria; ensure patients are told, in language they understand, what was found and what happens next; track follow-up imaging so nothing depends on memory; bring multidisciplinary expertise — radiology, pulmonology, thoracic surgery, oncology — to the cases that warrant it; and measure its own performance so gaps surface before patients fall through them.
Biomarkers enter the pathway
A notable feature of the modern pathway the framework describes is validated biomarker testing. Blood-based tests, such as those developed by Biodesix, can help clinicians judge whether a nodule is likely benign or suspicious, refining decisions about who needs an invasive biopsy and who can be safely watched. Used well, such testing reduces unnecessary procedures — biopsies carry real risks and costs — while speeding answers for patients whose nodules genuinely threaten them. Patient-facing background on lung health is available from the American Lung Association.
The framework’s emphasis on measurement deserves emphasis of its own. Programmes are urged to track metrics such as time from detection to diagnosis, follow-up completion rates and stage at diagnosis. Those numbers are how a hospital learns whether its programme is actually shifting lung cancer earlier — the entire point — or merely generating activity. Readers following developments in structured care pathways can find more analysis at leintech.com.
Why This Is Hard in Practice
Anyone who has worked in a hospital will recognise the failure modes the framework is designed against. A nodule is noted in an emergency-department scan report at 2 a.m.; the patient is discharged for an unrelated problem; the recommendation for a follow-up scan in six months sits in a report nobody owns. Months or years later, the patient returns with symptoms, and the cancer that was once a seven-millimetre spot is now advanced. These are rarely failures of individual diligence — they are failures of system design, which is why CHEST is prescribing system design.
Building a real programme costs money and coordination: nurse navigators, tracking software, multidisciplinary conferences, and the political work of aligning departments that do not naturally share workflows. Smaller and rural hospitals face the steepest version of the challenge, and the framework’s stepwise structure is partly an acknowledgement of that — a route for institutions to build capability in stages rather than all at once.
The Screening Connection
Lung nodule programmes also sit downstream of lung cancer screening, which uses low-dose CT in people at high risk from smoking history. Screening only delivers its proven mortality benefit if what it finds is managed well; a screening programme feeding into a disorganised follow-up system wastes its own promise. As screening eligibility widens and scan volumes grow, the nodules multiply — and frameworks like CHEST’s move from useful to essential.
What Good Programmes Mean for Patients
Behind the operational language sits a human experience that clinicians in this field describe consistently: the scanxiety of the in-between. A patient told there is a spot on their lung, and that the plan is to look again in six months, lives those six months with a question mark over their health. Well-run programmes shorten uncertainty where they safely can, communicate timelines clearly, and give patients a named contact rather than a void — practical kindnesses that also happen to improve follow-up completion, because patients who understand a plan are far more likely to keep its appointments.
There is an equity dimension too. Incidental nodules are found on everyone, but organised follow-up has historically been most reliable for patients already well connected to a health system. A formal programme, with a registry that captures every nodule regardless of which door the patient entered through, is one of the more concrete tools hospitals have for making sure the anxious and the well-insured are not the only ones whose spots get followed.
The direction of travel in this field is toward integration: detection, risk models that combine imaging with biomarkers and clinical data, navigation, and rapid diagnosis operating as one pathway with a name, a team and a dashboard. CHEST’s six steps give hospitals the blueprint. The patients who will benefit are, for the most part, people who will never know a programme existed — only that a spot on a scan was noticed, followed, and dealt with in time.
